[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021002257A - Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. - Google Patents

Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.

Info

Publication number
MX2021002257A
MX2021002257A MX2021002257A MX2021002257A MX2021002257A MX 2021002257 A MX2021002257 A MX 2021002257A MX 2021002257 A MX2021002257 A MX 2021002257A MX 2021002257 A MX2021002257 A MX 2021002257A MX 2021002257 A MX2021002257 A MX 2021002257A
Authority
MX
Mexico
Prior art keywords
methyl
ylethynyl
pyridazin
imidazo
trifluoromethyl
Prior art date
Application number
MX2021002257A
Other languages
English (en)
Inventor
Christopher K Murray
Leonard W Rozamus
John J Chaber
Pradeep Sharma
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50929140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021002257(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Publication of MX2021002257A publication Critical patent/MX2021002257A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente describe formas cristalinas novedosas de la base libre de 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-N-{4-[(4-m etilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benzamida y monoclorhidrato de 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil- N-{4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benza mida, sus composiciones farmacéuticas y métodos para su preparación y uso.
MX2021002257A 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. MX2021002257A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261736543P 2012-12-12 2012-12-12
US201261737007P 2012-12-13 2012-12-13
US201361788208P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
MX2021002257A true MX2021002257A (es) 2021-05-27

Family

ID=50929140

Family Applications (10)

Application Number Title Priority Date Filing Date
MX2015007578A MX359147B (es) 2012-12-12 2013-12-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3-iletinil)-4-me til-n-(4-[ (4-metilpiperazin-1-il) metil]-3-(trifluorometil) fenil) benzamida y su sal de monoclorhidrato.
MX2021002258A MX2021002258A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002254A MX2021002254A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002255A MX2021002255A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002253A MX2021002253A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002257A MX2021002257A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002259A MX2021002259A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002256A MX2021002256A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002264A MX2021002264A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002261A MX2021002261A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.

Family Applications Before (5)

Application Number Title Priority Date Filing Date
MX2015007578A MX359147B (es) 2012-12-12 2013-12-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3-iletinil)-4-me til-n-(4-[ (4-metilpiperazin-1-il) metil]-3-(trifluorometil) fenil) benzamida y su sal de monoclorhidrato.
MX2021002258A MX2021002258A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002254A MX2021002254A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002255A MX2021002255A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002253A MX2021002253A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.

Family Applications After (4)

Application Number Title Priority Date Filing Date
MX2021002259A MX2021002259A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002256A MX2021002256A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002264A MX2021002264A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002261A MX2021002261A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.

Country Status (9)

Country Link
US (9) US9493470B2 (es)
JP (4) JP6447508B2 (es)
CN (2) CN105188701A (es)
CA (3) CA3022250A1 (es)
CL (1) CL2015001643A1 (es)
HK (1) HK1218878A1 (es)
MX (10) MX359147B (es)
NZ (1) NZ709648A (es)
WO (2) WO2014093579A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006331673B2 (en) 2005-12-23 2013-02-28 Ariad Pharmaceuticals, Inc. Bicyclic heteroaryl compounds
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US9725454B2 (en) 2013-07-04 2017-08-08 Sandoz Ag Crystalline forms of ponatinib hydrochloride
CN104496940B (zh) * 2014-01-06 2017-03-15 广东东阳光药业有限公司 一种制备bcr‑abl抑制剂中间体的方法
US11117883B2 (en) * 2016-12-15 2021-09-14 Ariad Pharmaceuticals, Inc. Benzimidazole compounds as c-Kit inhibitors
US10221184B2 (en) 2017-01-20 2019-03-05 Apicore Us Llc Polymorphs of ponatinib hydrochloride
US11072620B2 (en) 2017-06-20 2021-07-27 Apotex Inc. Crystalline forms of Ponatinib hydrochloride
FI3774844T3 (fi) * 2018-04-02 2023-04-04 Stealth Biotherapeutics Inc Elamipretidin synteesissä hyödyllisiä kiteisiä dipeptidejä
EP3781568A1 (en) 2018-06-22 2021-02-24 Johnson Matthey Public Limited Company Form of ponatinib
JP2022515705A (ja) 2018-11-01 2022-02-22 サイロス ファーマシューティカルズ， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の非共有結合性阻害剤を用いてバイオマーカーにより特定された患者におけるがんを処置する方法
WO2020223235A1 (en) 2019-04-29 2020-11-05 Incyte Corporation Mini-tablet dosage forms of ponatinib
CN111004240B (zh) * 2019-12-13 2020-12-01 山东铂源药业有限公司 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099067A (en) * 1988-08-05 1992-03-24 Northwestern University Use of ammonium formate as a hydrogen transfer reagent for reduction of chiral nitro compounds with retention of configuration
JP4903963B2 (ja) 1999-11-08 2012-03-28 シェーリング コーポレイション Ｎ−（４−ヒドロキシ−フェニル）−ｎ’−（４’−アミノフェニル）−ピペラジンを調製するためのプロセス
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
TW200418466A (en) 2002-11-06 2004-10-01 Smithkline Beecham Corp Chemical compounds
GB0230089D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
PE20051046A1 (es) 2003-11-28 2006-01-11 Novartis Ag Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
NZ546782A (en) 2003-12-05 2010-04-30 Biovitrum Ab Improved synthesis of 2-substituted adenosines such as spongosine
WO2005060969A1 (en) 2003-12-24 2005-07-07 Astrazeneca Ab Pyrimidines with tie2 (tek) activity
DE602004018193D1 (de) 2003-12-24 2009-01-15 Astrazeneca Ab Pyrimidine mit tie2 (tek) aktivität
UA85405C2 (ru) 2004-04-07 2009-01-26 Эплайд Рисерч Системз Эрс Холдинг Н.В. Производные 1,1'-(1,2-этиндиил)бис-бензола как ингибиторы ртр-1в
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
WO2006103449A2 (en) 2005-03-31 2006-10-05 Astrazeneca Ab Saminopyrimidine derivates with tie2 inhibiting activity
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
CA2618513A1 (en) 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
SI1973545T1 (sl) * 2005-12-23 2013-04-30 Ariad Pharmaceuticals, Inc. Spojine bicikličnega heteroarila
AU2006331673B2 (en) 2005-12-23 2013-02-28 Ariad Pharmaceuticals, Inc. Bicyclic heteroaryl compounds
WO2007133560A2 (en) 2006-05-08 2007-11-22 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
EP2024366B1 (en) 2006-05-08 2015-09-16 Ariad Pharmaceuticals, Inc. Monocyclic heteroaryl compounds
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
WO2010124047A1 (en) * 2009-04-23 2010-10-28 Wyeth Llc Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mglur5)
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
EA201290255A1 (ru) * 2009-10-30 2013-04-30 Ариад Фармасьютикалз, Инк. Способы и композиции для лечения рака
JP2014513078A (ja) 2011-04-07 2014-05-29 アリアド・ファーマシューティカルズ・インコーポレイテッド パーキンソン病の治療方法及び治療用組成物
EA201391485A1 (ru) * 2011-04-07 2014-03-31 Ариад Фармасьютикалз, Инк. Способы и композиции для лечения нейродегенеративных заболеваний
JP2015514802A (ja) 2012-04-25 2015-05-21 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｒａｆキナーゼ媒介疾患用の方法及び組成物
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Also Published As

Publication number Publication date
US11192895B2 (en) 2021-12-07
US20190169196A1 (en) 2019-06-06
US20240083902A1 (en) 2024-03-14
JP7042175B2 (ja) 2022-03-25
WO2014093583A2 (en) 2014-06-19
MX2021002264A (es) 2021-05-27
US10125136B2 (en) 2018-11-13
US9493470B2 (en) 2016-11-15
MX359147B (es) 2018-09-17
JP2018168191A (ja) 2018-11-01
US20210277012A1 (en) 2021-09-09
US20210024527A1 (en) 2021-01-28
CN115043843A (zh) 2022-09-13
US11384086B2 (en) 2022-07-12
US11279705B2 (en) 2022-03-22
MX2021002256A (es) 2021-05-27
HK1218878A1 (zh) 2017-03-17
JP7352841B2 (ja) 2023-09-29
US20210277011A1 (en) 2021-09-09
US11192896B2 (en) 2021-12-07
MX2021002259A (es) 2021-05-27
MX2015007578A (es) 2016-03-21
CL2015001643A1 (es) 2015-10-02
JP2022037122A (ja) 2022-03-08
US10662197B2 (en) 2020-05-26
CA3022250A1 (en) 2014-06-12
JP6447508B2 (ja) 2019-01-09
JP2023179498A (ja) 2023-12-19
MX2021002255A (es) 2021-05-27
US11192897B2 (en) 2021-12-07
WO2014093579A2 (en) 2014-06-19
MX2021002254A (es) 2021-05-27
NZ709648A (en) 2020-05-29
WO2014093583A3 (en) 2014-08-07
MX2021002261A (es) 2021-05-27
US20170190707A1 (en) 2017-07-06
US20210340149A1 (en) 2021-11-04
CN105188701A (zh) 2015-12-23
JP2016503010A (ja) 2016-02-01
US20210277010A1 (en) 2021-09-09
MX2021002253A (es) 2021-05-27
CA2815506C (en) 2018-12-11
CA3167093A1 (en) 2014-06-12
US20150315194A1 (en) 2015-11-05
CA2815506A1 (en) 2014-06-12
WO2014093579A3 (en) 2014-07-10
MX2021002258A (es) 2021-05-27

Similar Documents

Publication Publication Date Title
MX2021002253A (es) Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
PH12017500166A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
NZ631112A (en) Crystalline bromodomain inhibitors
MX2014005635A (es) Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida.
IN2014DN09352A (es)
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
IN2014DN09348A (es)
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
HK1214822A1 (zh) 新型 苄氧基 苯基 己- -炔酸衍生物、其製備方法、和包括其作為有效成分的用於預防和治療代謝性疾病的藥物組合物
PH12018501236A1 (en) Pharmaceutical composition comprising a potent inhibitor urat1
IN2014DN09347A (es)
PH12018501331A1 (en) Crystalline forms of thienopyrimidine compound
PH12017501832A1 (en) Stabilized pharmaceutical composition
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
MX2014002141A (es) Carboxamidas de n-(5-cicloalquil - o 5-heterociclil-)-piridin-3-il o.
IN2013CH01248A (es)
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids